PharVision Advisers’s Mitek Systems MITK Stock Holding History

PharVision Advisers’s Portfolio MITK Stock Details MITK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,655	Closed	-$144K	–	431
2025 Q4	$144K	Buy	+13,655	New	+$129K	0.07%	618
2025 Q1	–	Sell	-11,870	Closed	-$132K	–	425
2024 Q4	$132K	Buy	+11,870	New	+$111K	0.11%	357

Other funds holding MITK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

PharVision Advisers's MITK Position: Q1 2026 in Review

PharVision Advisers sold out of Mitek Systems (MITK) in Q1 2026, closing a stake of 13,655 shares — an estimated $144K sold.

PharVision Advisers first reported a position in MITK in Q4 2024 and held it in 2 quarters. The position peaked at $144K in Q4 2025. 191 funds tracked by Wall St. Rank hold MITK as of Q1 2026.

PharVision Advisers reported no remaining Mitek Systems position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 13,655 Mitek Systems shares in Q1 2026, an estimated $144K.
PharVision Advisers first reported a position in Mitek Systems in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Mitek Systems position peaked at $144K in Q4 2025.
191 funds tracked by Wall St. Rank held Mitek Systems as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.